Clinical Research Study Finder

Children's Hospital of Philadelphia leads or participates in hundreds of clinical research studies and clinical trials. Many of the studies that are currently enrolling patients can be found in this database. Use this finder to learn more about the purpose of these studies and clinical trials, find out who can participate, and tell us you're interested in enrolling.

Find a Clinical Research Study

121 - 130 of 162

Online Mindfulness Course for Pediatric IBD

Inflammatory Bowel Disease (IBD) can sometimes add stress to your life and that may affect your physical symptoms of pain and stool habits. In this study, we want to know if practicing mindfulness via an online Mindfulness-based stress reduction (MBSR) course taught by a trained teacher can help with your IBD. If you are a patient with IBD, who is between 12-19 years of age, you might be eligible to participate in an 8 week long MBSR group course online. You will answer a series of questionnaires and submit stool samples 3 times over the course of the study, and you will also participate in 1 focus group to discuss your experience in the study. You will be compensated for your participation.

Ribociclib With Everolimus And Dexamethasone For Relapsed ALL

CHOP, in collaboration with Dana-Farber Cancer Institute, is conducting a study for children, adolescents, and young adults up to 31 years old, with relapsed or refractory acute lymphoblastic leukemia. This clinical trial is adding the study drugs ribociclib and everolimus to a standard relapse chemotherapy regimen. For more information about this study, including specific eligibility criteria, please visit clinicaltrials.gov. To hear more about this and other available trails or get any questions answered please contact our Cancer Intake Specialist by phone at 267-426-0762 or email Oncointake@email.chop.edu.

Daratumumab for T-cell ALL

CHOP, in collaboration with Janssen Research & Development, is conducting a study for children and young adults up to 30 years old, with relapsed or refractory precursor T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma. This clinical trial is adding the study drug, daratumumab, to a standard relapse chemotherapy regimen. For more information about this study, including specific eligibility criteria, please visit clinicaltrials.gov and search for "NCT03384654". To hear more about this and other available trails or get any questions answered please contact our Cancer Intake Specialist by phone at 267-426-0762 or email Oncointake@email.chop.edu.

RGX-111 Gene Therapy in Patients With Mucopolysaccharidosis Type I (MPS I)

This study will evaluate the safety andtolerability of RGX-111 in patients with Mucopolysaccharidosis Type I with aneurocognitive deficit that are at least 4 months old. This study involvesadministration of the RGX-111, general anesthesia, lumbar puncture, blooddraws, MRI, ultrasound, electrocardiogram, echocardiogram, hearing test, andchart review. If you have questions or would like to learn more about thestudy, please contact the Principal Investigator, Dr. Ficicioglu at (215)590-3376. 

RGX-121 Gene Therapy in Patients With MPS II (Hunter Syndrome)

The purpose of this study is to look at the safety and tolerability of RBX-121, a one-time gene therapy, in subjects with MPS II (Hunter Syndrome). You may be eligible for this study if you are a male between the ages of 4 months to 5 years old. Reimbursement for travel and research procedures will be provided. This study involves blood draws, interviews, urine collection, genetic testing, general anesthesia, lumbar punctures, MRI, gene therapy, lumbar puncture, ultrasound, ECG/echocardiogram and physical and neurological examinations. If you have questions or would like to learn more about the study, please contact the study team at MetabolismResearch@email.chop.edu.

1. Healthy Children Needed for Single Study Visit on Immunometabolic Dysregulation

Healthy control children are needed to help participate in a study on Immunometabolic Dysregulation. The study involves one visit to CHOP to take your child's height and weight, learn more about their medical history, and take a blood sample. The goal of this study is to better understand how immune function changes throughout childhood. Our goal is to find which factors may influence the immune system by comparing patients who have problems with their immune system with those who do not. Participating in this study helps CHOP to advance the health and well-being of children in our community with a focus on those with immunometabolic dysregulation.

Autism ETA Cohort Study

Parents and their child between 16 and 21 on the autism spectrum are both asked to partner with us for this study as we learn more about the decisions you make about transportation, including driving. We also hope to learn about how transportation influences quality of life and other outcomes. First, parents will answer questions about themselves and their child. Then, both parents and their child will complete up to six surveys over the course of two years. The surveys will ask about your thoughts and experiences with transportation and driving, quality of life, relationships, and other outcomes.

MELAS Study

The purpose of this research is to investigate study drug IW-6463 in patients with Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-Like Episodes (MELAS). IW-6463 is not approved by the U.S. Food and Drug Administration for any use.

The study period will last for approximately 75 days and will include at least 3 to 6 on-site visits at the Children’s Hospital of Philadelphia (CHOP), where participants will be provided the study drug and monitored for safety.

For more information, please contact Sara Nguyen at nguyens2@email.chop.edu

REN001 for Adults with Primary Mitochondrial Myopathy

The purpose of this new clinical trial is to investigate study drug “REN001” in adult patients with Primary Mitochondrial Myopathy.  REN001 is currently not approved by the U.S. Food and Drug Administration nor any other regulatory agencies for this disease; it is considered an experimental drug.

The study period will last for approximately 9 months and will include at least 4 outpatient visits at CHOP, where participants will be provided the study drug or placebo and monitored for safety.  The study also involves blood and urine tests, cardiac tests, physical exercise tests, and other study procedures.  For more information: https://www.clinicaltrials.gov/ct2/show/NCT04535609

Participants will be able to receive travel support and reimbursement for related expenses.

Humanized CART19 Phase 2 Trial

This purpose of this study isto determine the efficacy of humanized CD19 CAR  T cells (huCART19) in pediatric and youngadult patients with high-risk relapsed or refractory B-cell acute lymphoblasticleukemia (B-ALL). You may be eligible to participate if you are between theages of 1-29 years with CD19-expressing B-ALL that is refractory tochemotherapy, has relapsed in the bone marrow <36 months from diagnosis,relapsed more than once, or relapsed after bone marrow transplant or afterprevious CAR T cell therapy. This study involves the administration of thestudy drug, blood draws, assessment of leukemia response, chart reviews, andquestionnaires. Reimbursement for travel may be provided. If you have questionsor would like to learn more about the study, please contact the CancerImmunotherapy Program at (215) 425-7193. The Principal Investigator is Dr. ShannonMaude and the Immunotherapy Nurse Navigator is Brooke Leibfreid, RN.


Pages